NanoViricides (NNVC) Prices 1.4M Share Common Stock Offering at $7.30/Each

NanoViricides, Inc. (NYSE: NNVC), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has entered into a securities purchase agreement with several institutional investors for the issuance and sale of 1,400,000 shares of its common stock at a price of $7.30 per share, for aggregate gross proceeds of approximately $10.22 million, in a registered direct offering.

Maxim Group LLC and Kingswood Capital Markets, a division of Benchmark Investments, Inc., are acting as co-placement agents for the offering.

The offering is expected to close on or about May 22, 2020, subject to the satisfaction of customary closing conditions.

The offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-237370) previously filed and declared effective by the Securities and Exchange Commission (the "SEC"). The offering of the shares of common stock will be made only by means of a prospectus supplement that forms a part of the registration statement.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such
jurisdiction.

You May Also Be Interested In

• Qualcomm files to resell 17.8M shares tied to Modular acquisition
• Churchill Capital Corp XIII prices $360 million IPO on Nasdaq
• Westinghouse Electric files confidential IPO registration with SEC